Switch theme
Sign up to access all valuation multiples
Guerbet SA is a healthcare company that manufactures and markets medical imaging contrast agents destined for diagnostic purposes. Its products include medical imaging contrast products for x-ray imaging, magnetic resonance imaging, ultrasound imaging and for nuclear medicine. The company markets its products under the brand names such as Xenetix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol.
1926
981
LTM Revenue $913M
LTM EBITDA $132M
$594M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Guerbet has a last 12-month revenue of $913M and a last 12-month EBITDA of $132M.
In the most recent fiscal year, Guerbet achieved revenue of $855M and an EBITDA of $110M.
Guerbet expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Guerbet valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $827M | $855M | XXX | XXX | XXX |
| Gross Profit | $556M | $600M | XXX | XXX | XXX |
| Gross Margin | 67% | 70% | XXX | XXX | XXX |
| EBITDA | $107M | $110M | XXX | XXX | XXX |
| EBITDA Margin | 13% | 13% | XXX | XXX | XXX |
| Net Profit | $35.1M | -$44.2M | XXX | XXX | XXX |
| Net Margin | 4% | -5% | XXX | XXX | XXX |
| Net Debt | $213M | $267M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Guerbet's stock price is EUR 19 (or $21).
Guerbet has current market cap of EUR 245M (or $263M), and EV of EUR 553M (or $594M).
See Guerbet trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $594M | $263M | XXX | XXX | XXX | XXX | $1.61 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Guerbet has market cap of $263M and EV of $594M.
Guerbet's trades at 0.7x LTM EV/Revenue multiple, and 4.5x LTM EBITDA.
Analysts estimate Guerbet's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Guerbet and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $594M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | 5.4x | XXX | XXX | XXX |
| P/E | 10.3x | XXX | XXX | XXX |
| P/E/Growth | 0.6x | XXX | XXX | XXX |
| EV/FCF | -20.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGuerbet's NTM/LTM revenue growth is 4%
Guerbet's revenue per employee for the last fiscal year averaged $0.9M, while opex per employee averaged $0.6M for the same period.
Over next 12 months, Guerbet's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Guerbet's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Guerbet and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 17% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.9M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 69% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Guerbet acquired XXX companies to date.
Last acquisition by Guerbet was XXXXXXXX, XXXXX XXXXX XXXXXX . Guerbet acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Guerbet founded? | Guerbet was founded in 1926. |
| Where is Guerbet headquartered? | Guerbet is headquartered in France. |
| How many employees does Guerbet have? | As of today, Guerbet has 981 employees. |
| Is Guerbet publicy listed? | Yes, Guerbet is a public company listed on PAR. |
| What is the stock symbol of Guerbet? | Guerbet trades under GBT ticker. |
| When did Guerbet go public? | Guerbet went public in 1989. |
| Who are competitors of Guerbet? | Similar companies to Guerbet include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Guerbet? | Guerbet's current market cap is $263M |
| What is the current revenue of Guerbet? | Guerbet's last 12-month revenue is $913M. |
| What is the current EBITDA of Guerbet? | Guerbet's last 12-month EBITDA is $132M. |
| What is the current EV/Revenue multiple of Guerbet? | Current revenue multiple of Guerbet is 0.7x. |
| What is the current EV/EBITDA multiple of Guerbet? | Current EBITDA multiple of Guerbet is 4.5x. |
| What is the current revenue growth of Guerbet? | Guerbet revenue growth between 2023 and 2024 was 3%. |
| Is Guerbet profitable? | Yes, Guerbet is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
